Specifically, candesartan converts microglia to the M2 phenotype, which reduces stroke-induced neuronal injury by inhibiting TLR4 expression, IKBα and p65 phosphorylation, and NF-κB/p65 nuclear translocation in a TLR4/NF-κB dependent mechanism (Qie et al., 2020). The gene discussed is TLR4; the disease is stroke disorder.